Alveolus Bio

Alveolus Bio secures strategic investment from Shilpa Medicare to advance into pulmonary therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies

Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a promi

/PRNewswire/ -- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL,...

CAMBRIDGE, Mass. and BIRMINGHAM, Ala., Dec. 8, 2023/ PRNewswire/-- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and synthetic biology to deve

Birmingham, February 11, 2022 - Alveolus Bio announced today Dr. Vivek Lal, Founder & Chief Executive Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually

Birmingham, January 5, 2022 - Alveolus Bio today announced that it will be presenting virtually at the Biotech Showcase 2022 conference, which runs during JP Morgan Healthcare Week. With healthcare's most important event going virtual yet again this year,

Emerging evidence indicates that early life events can increase the risk for developing chronic obstructive pulmonary disease (COPD). Using an inducible transgenic mouse model for NF-κB activation in the airway epithelium, we found that a brief period of

The pathogenesis of bronchopulmonary dysplasia (BPD) is not well understood. We previously identified differences in the airway microbiome at birth between preterm infants who were BPD predisposed versus those who were BPD resistant. In this study, we att

Alterations of pulmonary microbiome have been recognized in multiple respiratory disorders. It is critically important to ascertain if an airway microbiome exists at birth and if so, whether it is associated with subsequent lung disease. Investigators fou